Correction: J Exp Clin Cancer Res 43, 251 (2024)
10.1186/s13046-024-03165-x
Following publication of the original article [1], the authors found an error in the affiliation of the 5th author, Zahid Rafiq. He was mistakenly assign to Affiliation 1. The details are given below:
Incorrect affiliation:
1 Department of Radiation Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.
Correct affiliation:
2 Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
This correction does not affect the overall result or conclusion of the article. The original article [1] has been corrected.
Footnotes
The online version of the original article can be found at 10.1186/s13046-024-03165-x.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Kewen He, Email: hekewen9144@foxmail.com.
James W. Welsh, Email: jwelsh@mdanderson.org
Reference
- 1.He K, Puebla-Osorio N, Barsoumian HB, et al. Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy. J Exp Clin Cancer Res. 2024;43:251. 10.1186/s13046-024-03165-x. 10.1186/s13046-024-03165-x [DOI] [PMC free article] [PubMed] [Google Scholar]